Shares of Johnson & Johnson JNJ,
rose 0.9% in trading on Monday as the company approached the expected release of interim results from a late-stage clinical trial evaluating the single-dose COVID-19 vaccine candidate. J&J said it would share the findings of the Phase 3 trial by mid-December, which is the third company testing coronavirus vaccines in the U.S. to announce the results of a rigorous Phase 3 trial . The other two vaccines, developed by BioNTech’s BNTX,
/ Pfizer Inc. PFE,
and Modern Inc. MRNA,
are both mRNA-based vaccines, which received emergency approval from the Food and Drug Administration in December. J&J said in December that they would submit an emergency authorization for the experimental adenovirus-based vaccine in February if the results were ready by the end of January. The company is expected to announce its earnings for the fourth quarter and full year on Tuesday. J & J’s share has risen by 10.9% over the past year, while the S&P 500 SPX,
is 15.6% higher.
